Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $15.57
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the […]
More Stories
Dream Industrial Real Estate Invest Trst (TSE:DIR.UN) Price Target Lowered to C$14.50 at Raymond James
Dream Industrial Real Estate Invest Trst (TSE:DIR.UN – Free Report) had its price target lowered by Raymond James from C$15.75...
Stifel Nicolaus Issues Pessimistic Forecast for Algoma Steel Group (TSE:ASTL) Stock Price
Algoma Steel Group (TSE:ASTL – Free Report) had its target price lowered by Stifel Nicolaus from C$22.00 to C$21.00 in...
StockNews.com Initiates Coverage on Mannatech (NASDAQ:MTEX)
StockNews.com initiated coverage on shares of Mannatech (NASDAQ:MTEX – Free Report) in a report released on Monday morning. The brokerage...
Symbolic Logic (NASDAQ:EVOL) Coverage Initiated at StockNews.com
StockNews.com started coverage on shares of Symbolic Logic (NASDAQ:EVOL – Free Report) in a report released on Monday morning. The...
Cantaloupe (NASDAQ:USAT) Earns Hold Rating from Analysts at StockNews.com
StockNews.com began coverage on shares of Cantaloupe (NASDAQ:USAT – Free Report) in a research note issued to investors on Monday....
Retail Opportunity Investments (NASDAQ:ROIC) Now Covered by StockNews.com
StockNews.com assumed coverage on shares of Retail Opportunity Investments (NASDAQ:ROIC – Free Report) in a research report sent to investors...